<DOC>
	<DOCNO>NCT00192023</DOCNO>
	<brief_summary>The study phase IIIb multicentre , randomise , placebo control , trial paediatric patient Attention-Deficit/Hyperactivity ( ADHD ) Oppositional Defiant Disorder ( ODD ) . The primary aim study evaluate efficacy atomoxetine improve ADHD ODD symptoms patient non responder previous psychological intervention parent support . Moreover , potential role atomoxetine treat psychiatric comorbid condition associate ADHD ODD assess .</brief_summary>
	<brief_title>An Italian Study Efficacy Atomoxetine Treatment Children Adolescents With Attention-Deficit/Hyperactivity Disorder ( ADHD ) Comorbid Oppositional Defiant Disorder ( ODD ) .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Child adolescent patient , male female outpatient , least 6 year age , must yet reach 16th birthday prior Visit 1 , inform consent obtain . Patients must meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) diagnostic criterion ADHD ( subtype ) ODD score least 1.5 standard deviation age norm diagnostic subtype use publish norm Swanson , Nolan Pelham Questionnaire : AttentionDeficit/Hyperactivity Disorder ( SNAPIV ADHD ) Subscale score Visit 1 2 . They must also SNAPIV ODD subscale score least 15 Visit 1 Visit 2 . Other comorbid condition , allow diagnosis ADHD ODD must patient 's primary diagnosis . Patients must normal intelligence judgment investigator ( , without general impairment intelligence likely , investigator 's judgement , achieve score great equal 70 Intelligence Quotient ( IQ ) test ) . The administration formal IQ test entry requirement study . Specific learn disability consider general impairment intelligence . Patients weigh less 20 kilogram ( kg ) study entry ( Visit 1 ) . Patients documented history Bipolar I II disorder , history psychosis pervasive development disorder . Patients history seizure disorder ( febrile seizure ) patient take ( currently take ) anticonvulsant seizure control eligible participate . Patients serious suicidal risk assess investigator . Patients , investigator 's judgment , likely need psychotropic medication apart drug study , include healthfood supplement investigator feels central nervous system activity ( example , St. John 's Wort , melatonin ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>